Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Our ‘2022 in Review’ Focus highlights the year’s key developments in the cancer field in news articles, specially commissioned comment and opinion pieces, and an overview of the year’s most striking cancer research curated by the Nature Cancer editorial team.
The Biden administration’s cancer-focused initiatives were reinvigorated this year with the relaunch of the Cancer Moonshot and with ARPA-H plans taking shape. But after a bumpy year of leadership turnover and missteps in funding proposals, how these efforts will play out remains to be seen.
Deeper insights into context-specific cancer cell states and the mechanisms that underlie the phenotypic plasticity of different cancer types are key to tackling tumor formation, therapy resistance and recurrence after therapy.
The true impact of a paper, a researcher’s work or a journal’s value cannot be captured by any one metric but requires a more nuanced approach that combines quantitative and qualitative measures.
The US Supreme Court’s ruling to overturn Roe v. Wade will affect patients with cancer and cancer care providers across the United States. In this time of uncertainty, it is imperative to protect health rights and evidence-based care.
The advent of immunotherapy has revolutionized the cancer field, but it is not without its challenges. In this issue, we launch our Series on Cancer Immunotherapy presenting commissioned Reviews and opinion pieces on the latest advances and efforts to expand the palette of immunotherapies and their clinical translation.
Nature Cancer and the Nature journals are raising the standards on reporting on sex and gender in research. Starting this June, authors will be prompted to provide details on how sex and gender were considered in study design.
The advent of EGFR inhibitors has been a game changer in clinical oncology. However, differing sensitivity to different mutations, resistance and adverse effects continue to impede decisive treatment of mutant EGFR–driven cancers, which highlights the need for advanced and innovative EGFR-targeting approaches.
A deeper understanding of the specific tumor context and microenvironment, the underlying tumor immunology, and barriers to effective treatment, including therapy resistance and adverse effects, is essential to the development of improved immunotherapy modalities and regimens.
Robust and faithful preclinical models are essential for understanding the underlying biology of human cancer and for devising new and improved therapies.
A deeper understanding of the molecular and cellular underpinnings of metastatic disease and a renewed focus on metastasis-targeting therapeutic approaches raise hopes for improved clinical translation.
